Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF – Get Free Report)’s share price traded up 69.9% during trading on Tuesday . The company traded as high as $16.00 and last traded at $16.00. 200 shares traded hands during trading, a decline of 50% from the average session volume of 400 shares. The stock had previously closed at $9.42.
Santhera Pharmaceuticals Stock Performance
The stock has a fifty day moving average of $9.81 and a 200 day moving average of $10.70.
Santhera Pharmaceuticals Company Profile
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD).
Featured Stories
- Five stocks we like better than Santhera Pharmaceuticals
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Undervalued Stocks You Can Buy at a Discount Now
- The 3 Best Fintech Stocks to Buy Now
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Santhera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santhera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
